New option to reduce damage in NMOSD attacks

Credibility

Interest

Key Takeaway

Giving a C5 complement inhibitor (eculizumab or ravulizumab) during or soon after a sudden NMOSD attack helped most patients stabilize and often improve their disability.

What They Found

Researchers looked at 33 people with NMOSD who had attacks and were treated with C5 inhibitors during or shortly after the attack. Most patients had serious attacks of the spinal cord or optic nerve that caused big drops in function, but after treatment many improved over weeks to months. About half had good recovery, some had moderate recovery, and a few had little or no recovery. Starting treatment earlier (within about three weeks) tended to give better results, although the benefit size is uncertain. Many patients also had plasma exchange (a blood-cleaning procedure), which was linked to better overall responses but did not clearly raise the chance of a full good recovery on its own.

Who Should Care and Why

People with NMOSD and their caregivers should care because this study suggests an additional option to try during severe attacks when first treatments don’t work well. Think of an attack like a house fire: standard treatments try to put out flames, and C5 inhibitors may help stop the fire from spreading further to keep more of the house (nervous system) from being damaged. Patients who have aggressive attacks, do not fully respond to steroids or plasma exchange, or have frequent relapses may benefit most from asking their neurologist about C5 inhibitors. Caregivers can use this information to discuss treatment timing and advocate for faster decisions, since earlier treatment tended to help more. Healthcare providers may consider adding C5 inhibition to their acute-attack toolbox, especially when standard care is not stopping the attack.

Important Considerations

This was a retrospective case series, not a randomized trial, so it cannot prove the treatment works for everyone—there may be other reasons patients improved. The number of patients was small and treatment timing varied, which makes it hard to know exactly how much earlier treatment helps. Some patients also had plasma exchange and other therapies, so we can’t clearly separate the effect of the C5 drugs from those other treatments.

Categories:

Treatment Updates Clinical Trials Specific Symptoms

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology(R) neuroimmunology & neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News